Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody

Journal of Immunology

Volumn 181, Issue 9, 2008, Pages 6625-6634

  Hernández, Ana María ^a   Toledo, Darién ^a   Martínez, Darel ^a   Griñán, Tania ^a   Brito, Victor ^a   Macías, Amparo ^a   Alfonso, Sailyn ^b   Rondón, Teresa ^a   Suárez, Eduardo ^a   Vázquez, Ana María ^a   Pérez, Rolando ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Cardiocentro Ernesto Che Guevara Hospital Celestino Hernández Robau   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CISPLATIN; COMPLEMENT; GANGLIOSIDE GM3; HYPERIMMUNE GLOBULIN; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY 1E10; NEUGC GANGLIOSIDE GM3; SULFATIDE; UNCLASSIFIED DRUG; VINBLASTINE; ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; N GLYCOLOYLNEURAMINYLLACTOSYLCERAMIDE; N-GLYCOLYLNEURAMINYLLACTOSYLCERAMIDE;

ANIMAL CELL; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOREACTIVITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SURVIVAL TIME; TARGET CELL DESTRUCTION; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BLOOD; CELL DEATH; DOG; DOSE RESPONSE; GENETICS; HORSE; IMMUNOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE, TUMOR; DOGS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; G(M3) GANGLIOSIDE; HORSES; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 58149456558     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.9.6625     Document Type: Article

References (60)

1. Jemal, A., T. Murray, E. Ward, A. Samuels, R. C. Tiwari, A. Ghafoor, E. J. Feuer, and M. J. Thun. 2005. Cancer statistics. CA Cancer J. Clin. 55: 10-30.
2. Parkin, D. M., F. Bray, J. Ferlay, and P. Pisani. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
3. Carney, D. N., and H. H. Hansen. 2000. Non-small cell lung cancer: stalemate or progress? N. Engl. J. Med. 343: 1261-1262. (Pubitemid 30792755)
4. Schiller, J. H., D. Harrington, C. P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu, and D. H. Johnson. 2002. Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346: 92-98.
5. Reck, M. 2005. Current approaches in chemotherapy of advanced and metastatic non-small cell lung (NSCLC). Anticancer Res. 25: 1501-1503. (Pubitemid 40896755)
6. D'Addario, G., M. Pintilie, N. B. Leighl, R. Feld, T. Cerny, and F. A. Shepherd. 2005. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J. Clin Oncol. 23: 2926-2936. (Pubitemid 46224111)
7. Cobo, M., E. Villar, I. Ales, S. Gil, J. Alcalde, V. Gutierrez, F. Carabantes, A. Montesa, J. J. Breton, and M. Benavides. 2006. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Clin. Transl. Oncol. 8: 742-749.
8. Irie, A., and A. Suzuki. 1998. CMP-Neu-acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem. Biophys. Res. Commun. 248: 330-333. (Pubitemid 28386421)
9. Olson, M. V., and A. Varki. 2003. Sequencing the chimpanzee genome: insights into human evolution and disease. Nat. Rev. Genet. 4: 20-28.
10. Malykh, Y., R. Schauer, and L. Shawn. 2001. Neu-glycolylneuraminic acid in human tumors. Biochimie 83: 623-634.
11. Marquina, G., H. Waki, L. E. Fernández, K. Kon, A. Carr, O. Valiente, R. Pérez, and S. Ando. 1996. Gangliosides expressed in human breast cancer. Cancer Res. 56: 5165-5171. (Pubitemid 26383031)
12. Miyake, M., K. Hashimoto, M. Ito, O. Ogawa, E. Arai, S. Itomi, and R. Kannagi. 1990. The abnormal occurrence and the differentiation-dependent distribution of N-acetyl, and N-glycolyl species of the ganglioside GM2 in human germ cell tumors: a study with specific monoclonal antibodies. Cancer 65: 499-505. (Pubitemid 20058367)
13. de León, J., A. Fernández, C. Mesa, M. Clavel, and L. E. Fernández. 2006. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother. 55: 443-450.
14. Jerne, N. K. 1974. Toward a network theory of the immune system. Ann. Immunol. 125C: 373-389.
15. Foon, K. A., J. Lutzky, R. N. Baral, J. R. Yannelli, L. Hutchins, A. Teitelbaum, O. L. Kashala, R. Das, J. Garrison, R. A. Reisfeld, and M. Bhattacharya-Chatterjee. 2000. Clinical and immune responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 18: 376-384.
16. Giaccone, G., C. Debruyne, E. Felip, P. B. Chapman, S. C. Grant, M. Millward, L. Thiberville, G. D'Addario, C. Coens, L. S. Rome, et al. 2005. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 23: 6854-6864. (Pubitemid 46260271)
17. Vázquez, A. M., A. Perez, A. M. Hernandez, A. Macias, M. Alfonso, G. Bombino, and R. Perez. 1998. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 17: 527-534. (Pubitemid 29024638)
18. Vázquez, A. M., M. Alfonso, B. Lanne, K. A. Karlsson, A. Carr, O. Barroso, L. E. Fernández, E. Rengifo, M. E. Lanio, C. Alvarez, et al. 1995. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 14: 551-556. (Pubitemid 26028517)
19. Moreno, E., B. Lanne, A. M. Vazquez, I. Kawashima, T. Tai, L. E. Fernandez, K. A. Karlsson, J. Angstrom, and R. Perez. 1998. Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology 8: 695-705. (Pubitemid 28331445)
20. Alfonso, M., A. Diaz, A. M. Hernandez, A. Perez, E. Rodriguez, R. Bitton, R. Perez, and A. M. Vázquez. 2002. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168: 2523-2529. (Pubitemid 34171859)
21. Neninger, E., R. M. Diaz, A. de la Torre, G. Saurez, M. R. Gabri, D. S. Alonso, B. Wilkinson, A. M. Alfonso, T. Crombet, R. Perez, and A. M. Vázquez. 2007. Active immunotherapy with 1E10 anti-Idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol. Ther. 6: 145-150. (Pubitemid 46641614)
22. Marquina, G., H. Waki, L. E. Fernández, K. Kon, A. Carr, O. Valiente, R. Pérez, and S. Ando. 1996. Gangliosides expressed in human breast cancer. Cancer Res. 56: 5165-5171. (Pubitemid 26383031)
23. Pérez, A., E. Mier, N. S. Santiago, A. M. Vázquez, and R. Pérez. 2002. A monoclonal antibody against NeuGc-containing gangliosides contains regulatory idiotope involved in the interaction with B and T cells. Mol. Immunol. 30: 103-112. (Pubitemid 35245388)
24. Bona, C., E. Heber-Katz, and W. Paul. 1981. Idiotype-anti idiotype regulation I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones. J. Exp. Med. 153: 951-967. (Pubitemid 11104742)
25. Vazquez, A. M., M. R. Gabri, A. M. Hernandez, D. F. Alonso, I. Beausoleil, D. E. Gómez, and R. Perez. 2000. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol. Rep. 7: 751-756.
26. Diaz, A., M. Alfonso, R. Alonso, G. Saurez, M. Troche, M. Catala, R. M. Diaz, R. Pérez, and A. M. Vázquez. 2003. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin. Immunol. 107: 80-89. (Pubitemid 36579371)
27. Guthmann, M. D., M. A. Castro, G. Cinat, C. Venier, L. Koliren, R. J. Bitton, A. M. Vázquez, and L. Fainboim. 2006. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J. Immunother. 29: 215-223.
28. Alfonso, S., R. M. Díaz, A. de la Torre, E. Santiesteban, F. Aguirre, K. Pérez, J. L. Rodríguez, M. C. Barroso, A. M. Hernández, D. Toledo, et al. 2007. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol. Ther. 6: 1847-1852. (Pubitemid 351590395)
29. Stults, C. L. M., C. C. Sweeley, and B. A. Macher. 1989. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol. 179: 167-214.
30. 3(NeuGc) in myelomas and hibridomas of mouse, rat and human origin. J. Biochem. 116: 64-73.
31. Vázquez, A. M., B. R. Tormo, M. Alfonso, A. Velandia, L. E. Fernández, R. Giscombe, Y. Ansotegui, M. Jeddi Tehrani, M. Cedeño, A. L. Toledo, et al. 1995. Characterization of ior C5 colorectal tumor associated antigen. Inmunología 14: 130-132.
32. Hernández, A. M., M. Rodriguez, A. López-Requena, I. Beausoleil, R. Pérez, and A. M. Vázquez. 2005. Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: a self versus non-self-matter. Immunobiology 210: 11-21. (Pubitemid 40862456)
33. Mittelman, A., Z. J. Chen, T. Kageshita, H. Yang, M. Yamada, L. Baskind, N. Goldberg, C. Puccio, T. Ahmed, Z. Arlin, and S. Ferrone. 1990. Active specific immunotherapy in patients with melanoma: a clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high molecular weight melanoma associated antigen monoclonal antibodies. J. Clin. Invest. 86: 2136-2144.
34. Aguillon, J. C., J. Contreras, A. Dotte, A. Cruzat, D. Catalan, L. Salazar, M. C. Molina, J. Guerrero, M. Lopez, L. Soto, et al. 2003. New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Méd. Chile 131: 1445-1453.
35. Livingston, P. O. 1995. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin. Cancer Biol. 6: 357-366.
36. Grant, S. C., M. G. Kris, A. M. Houghton, and P. B Chapman. 1999. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC-2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. 5: 1319-1323.
37. Yao, T. Z., M. Meyers, P. O. Livingston, A. Houghton, and P. Chapman. 1999. Immunization of melanoma patients with BEC2-Keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce Anti-GD3 ganglioside antibodies. Clin. Cancer Res. 5: 77-81.
38. Bowes, T., E. Wagner, J. Boffey, D. Nicholl, and L. Cochrane. 2002. Tolerance to self gangliósidos is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Infect. Immun. 70: 5008-5018. (Pubitemid 34907311)
39. Chen, Z., C. Radic, and U. Galili. 2000. Genes coding evolutionary novel anticarbohydrate antibodies: studies on anti-Gal production in α 1,3 galactosyltransferase knock out mice. Mol. Immunol. 37: 455-466. (Pubitemid 30951301)
40. Lunn, M. P., L. A. Johnson, S. E. Fromholt, S. Itonor, J. Huang, A. A. Vyas, and K. A. Sheikh. 2000. High affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization. J. Neurochem. 75: 404-412.
41. Chou, H., H. Takematsu, S. Díaz, J. Iber, E. Nickerson, K. L. Wright, E. Muchmore, D. L. Nelson, S. T. Warren, and A. Varki. 1998. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo- Pan divergence. Proc. Natl. Acad. Sci. USA 95: 11751-11756. (Pubitemid 28460486)
42. Irie, A., and A. Suzuki. 1998. CMP-Neu-acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem. Biophys. Res. Commun. 248: 330-333. (Pubitemid 28386421)
43. Olson, M. V., and A. Varki. 2003. Sequencing the chimpanzee genome: insights into human evolution and disease. Nat. Rev. Genet. 4: 20-28.
44. Bardor, M., D. H. Nguyen, S. Dias, and A. Varki. 2005. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 4228-4237. (Pubitemid 40288589)
45. Tangvoranuntakul, P., P. Ganneux, S. Díaz, M. Bardor, N. Varki, A. Varki, and E. Muchmore. 2003. Human uptake and incorporation of an immunogenic non-human dietary sialic acid. Proc. Natl. Acad. Sci. USA 100: 12045-12050. (Pubitemid 37271512)
46. Yin, J. 2006. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res. 15: 2937-2945.
47. Lange, H., and H. Lemke. 1996. Induction of a non-oscilating, long lasting humoral immune response to an internal network antigen. Int. Immunol. 8: 683-688. (Pubitemid 26148289)
48. Rodríguez, M., L. Roque-Navarro, A. López-Requena, E. Moreno, C. Mateo de Acosta, R. Pérez, and A. M. Vázquez. 2007. Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. Immunobiology 212: 57-70. (Pubitemid 46158269)
49. Cohen, I. R. 2007. Biomarkers, self-antigens, and the immunological homunculus. J. Autoimmun. 29: 246-249.
50. Fagerberg, J., J. E. Frödin, P. Ragnhammar, M. Steinitz, H. Wigzell, and H. Mellstedt. 1994. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1): II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol. Immunother. 38: 149-159. (Pubitemid 24069223)
51. Brandlein, S., N. Rauschert, L. Rasche, A. Dreykluft, F. Hensel, E. Conzelmann, H. K. Muller-Hermelink, and H. P. Vollmers. 2007. The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low density lipoprotein. Mol. Cancer Ther. 6: 326-333. (Pubitemid 46206697)
52. Vollmers, H. P., and S. Brandlein. 2006. Natural IgM antibodies: from parias to parvenus. Histol. Histopathol. 21: 1355-1366.
53. Vollmers, H. P., and S. Brandlein. 2005. Death by stress: natural IgM-induced apoptosis. Methods Find. Exp. Clin. Pharmacol. 27: 185-191.
54. Retter, M. W., J. C. Johnson, D. W. Peckham, J. E. Bannink, C. S. Bangur, K. Dresser, F. Cai, T. M. Foy, N. A. Fanger, G. R. Fanger, et al. 2005. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res. 65: 6425-6434.
55. Aixinjueluo, W., K. Furukawa, Q. Zhang, K. Hamamura, N. Tokuda, S. Yoshida, R. Ueda, and K. Furukawa. 2005. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J. Biol. Chem. 280: 29828-29836. (Pubitemid 41179010)
56. Mone, A., C. Cheney, A. Banks, S. Tridanpani, and J. Byrd. 2006. AlemtuzumAb induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20: 272-279. (Pubitemid 43148665)
57. Bhat, N., M. Bieder, F. Stevenson, and N. Teng. 1996. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Clin. Exp. Immunol. 105: 183-190. (Pubitemid 26231843)
58. Herlyn, D., R. Somasundaram, W. Li, and H. Maruyama. 1996. Anti-idiotype cancer vaccines: past and future. Cancer Immunol. Immunother. 43: 65-76. (Pubitemid 26385223)
59. Somasundaram, R., J. Zaloudik, L. Jacob, A. Benden, M. Sperlagh, E. Hart, G. Marks, M. Kane, M. Mastrangelo, and D. Herlyn. 1995. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J. Immunol. 155: 3253-3261.
60. Birebent, B., E. Mitchell, N. Akis, W. Li, R. Somasundaram, E. Purev, D. Hoey, M. Mastrangelo, H. Maguire, D. Harris, et al. 2003. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 21: 1601-1612. (Pubitemid 36287592)